Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer

被引：0
|
作者：
Dimitrios Pectasides
Vasilios Karavasilis
George Papaxoinis
Georgia Gourgioti
Thomas Makatsoris
Georgia Raptou
Eleni Vrettou
Joseph Sgouros
Epaminontas Samantas
George Basdanis
Pavlos Papakostas
Dimitrios Bafaloukos
Vassiliki Kotoula
Haralambos P. Kalofonos
Chrisoula D. Scopa
George Pentheroudakis
George Fountzilas
机构：
[1] “Hippokration” Hospital,Oncology Section, Second Department of Internal Medicine
[2] Aristotle University of Thessaloniki School of Medicine,Department of Medical Oncology, “Papageorgiou” Hospital
[3] Section of Biostatistics,Division of Oncology, Department of Medicine
[4] Hellenic Cooperative Oncology Group,Department of Pathology
[5] Data Office,Third Department of Medical Oncology
[6] University Hospital,First Propaedeutic Department of Surgery, “AHEPA” Hospital
[7] University of Patras Medical School,Department of Medical Oncology
[8] Aristotle University of Thessaloniki School of Medicine,First Department of Medical Oncology
[9] “Agii Anargiri” Cancer Hospital,Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research
[10] Aristotle University of Thessaloniki School of Medicine,Department of Pathology
[11] “Hippokration” Hospital,Department of Medical Oncology
[12] “Metropolitan” Hospital,undefined
[13] Aristotle University of Thessaloniki School of Medicine,undefined
[14] University Hospital,undefined
[15] University of Patras Medical School,undefined
[16] Ioannina University Hospital,undefined
来源：
BMC Cancer | / 15卷
关键词：
Colorectal cancer; Adjuvant chemotherapy; Modified FOLFOX6; Capecitabine; Oxaliplatin; Prognosis; KRAS; Microsatellite instability;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer
    W Schippinger
    H Samonigg
    R Schaberl-Moser
    R Greil
    R Thödtmann
    J Tschmelitsch
    M Jagoditsch
    G G Steger
    R Jakesz
    F Herbst
    F Hofbauer
    H Rabl
    P Wohlmuth
    M Gnant
    J Thaler
    British Journal of Cancer, 2007, 97 : 1021 - 1027
  • [22] A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer
    Schippinger, W.
    Samonigg, H.
    Schaberl-Moser, R.
    Greil, R.
    Thoedtmann, R.
    Tschmelitsch, J.
    Jagoditsch, M.
    Steger, G. G.
    Jakesz, R.
    Herbst, F.
    Hofbauer, F.
    Rabl, H.
    Wohlmuth, P.
    Gnant, M.
    Thaler, J.
    BRITISH JOURNAL OF CANCER, 2007, 97 (08) : 1021 - 1027
  • [23] Efficacy and Safety of Capecitabine and Oxaliplatin (CapOX) as an Adjuvant Therapy in Japanese for Stage II/III Colon Cancer in a Group at High Risk of Recurrence in Retrospective Study
    Osawa, Hiroshi
    Handa, Naoko
    Minakata, Kunihiko
    ONCOLOGY RESEARCH, 2015, 22 (5-6) : 325 - 331
  • [24] Erratum: Adjuvant sequential methotrexate → 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer
    A Sobrero
    G Frassineti
    A Falcone
    L Dogliotti
    R Rosso
    F Di Costanzo
    P Bruzzi
    British Journal of Cancer, 2005, 93 : 733 - 733
  • [25] A prospective randomized phase III trial of adjuvant chemotherapy with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with stage II colon cancer
    Schippinger, W.
    Samonigg, H.
    Greil, R.
    Tschmelitsch, J.
    Steger, G.
    Jakesz, R.
    Gnant, M.
    Hofbauer, F.
    Rabl, H.
    Thaler, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [26] A phase I study of vorinostat (suberoylanilide hydroxamic acid) in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) in patients with advanced colorectal cancer (CRC)
    Fakih, M. G.
    Pendyala, L.
    Smith, P.
    Creaven, P.
    Toth, K.
    Zwiebel, J.
    Frankel, S.
    Litwin, A.
    Huffman, L.
    Egorin, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [27] Comparison between oxaliplatin therapy and capecitabine monotherapy for high-risk stage II-III elderly patients with colon cancer
    Park, Jueun
    Baik, HyungJoo
    Kang, Sang Hyun
    Seo, Sang Hyuk
    Kim, Kwang Hee
    Oh, Min Kyung
    Lee, Hong Sub
    Lee, Sang Heon
    Kim, Ki Hyang
    An, Min Sung
    ASIAN JOURNAL OF SURGERY, 2022, 45 (01) : 448 - 455
  • [28] Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial
    Schmoll, Hans-Joachim
    Tabernero, Josep
    Maroun, Jean
    de Braud, Filippo
    Price, Timothy
    Van Cutsem, Eric
    Hill, Mark
    Hoersch, Silke
    Rittweger, Karen
    Haller, Daniel G.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (32) : 3733 - +
  • [29] Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin - A prospective analysis
    Kuebler, J. Philip
    Colangelo, Linda
    O'Connell, Michael J.
    Smith, Roy E.
    Yothers, Greg
    Begovic, Mirsada
    Robinson, Bridget
    Seay, Thomas E.
    Wolmark, Norman
    CANCER, 2007, 110 (09) : 1945 - 1950
  • [30] Interim analysis of a phase II trial evaluating the safety and efficacy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer
    Danno, Katsuki
    Hata, Taishi
    Tamai, Koki
    Fujie, Yujiro
    Ide, Yoshihito
    Kim, Ho Min
    Ohnishi, Tadashi
    Morita, Shunji
    Yoshioka, Shinichi
    Kudo, Toshihiro
    Nishimura, Junichi
    Matsuda, Chu
    Akamatsu, Hiroki
    Mizushima, Tsunekazu
    Nezu, Riichiro
    Doki, Yuichiro
    Mori, Masaki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (04) : 777 - 785
12345